Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
1. Purpose:Our animal study demonstrated the effectiveness of subconjunctival injection of
bevacizumab in the inhibition of corneal neovasculization formation. The purpose of this
human interventional study is to report the treatment outcome of subconjunctival
injection of bevacizumab in patients with corneal neovascularization.
2. Material and methods: We enrolled 13 patients with unilateral or bilateral clinically
significant corneal neovascularization during Aug. 2007 to Jan. 2008. Subconjunctival
injection of bevacizumab once per month for at most 7 times was performed according to
clinical response.
3. Main outcome measurements: resolution of corneal neovascularization, reduction of lipid
infiltrate, improved visual acuity.